GSK to option Cellzome's kinase inhibitors for inflammation
GlaxoSmithKline has received options to exclusively license several anti-inflammatory kinase inhibitors discovered by German biotech Cellzome. Four kinase targets have already been identified, and the companies may jointly select three more.
Drug Discovery Tools
- Drug Discovery Tools
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.